Mycophenolate Sodium

• CAT Number: M014857
• CAS Number: 37415-62-6
• Molecular Formula: C17H19NaO6
• Molecular Weight: 342.323
• Purity: ≥95%
• Synonyms: mycophenolicacidmonosodiumsalt;mycophenolicmonosodiumsalt;sodiummycophenolate;MYCOPHENOLATE SODIUM;4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy-6-Methoxy-7-Methyl-3-oxo-5-isobenzofuranyl)-4-Methyl-,sodiuM salt;4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy-6-M
• Target: Anti-infection
• Storage: -20°C
• IUPAC Name: sodium;(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
• InChI: InChI=1S/C17H20O6.Na/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3;/h4,20H,5-8H2,1-3H3,(H,18,19);/q;+1/p-1/b9-4+
• InChIKey: DOZYTHNHLLSNIK-JOKMOOFLSA-M
• SMILES: CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)[O-])OC.[Na+]

Mycophenolate sodium(CAT: M014857) is an immunosuppressive medication used in transplant medicine and autoimmune diseases. Its mode of action involves inhibiting the proliferation of certain immune cells, such as T and B lymphocytes, by blocking an enzyme called inosine monophosphate dehydrogenase (IMPDH). By doing so, mycophenolate sodium suppresses the immune response, which is beneficial in preventing rejection of transplanted organs and treating autoimmune conditions like lupus and rheumatoid arthritis.

Reference

1: Deuter CME, Engelmann K, Heiligenhaus A, Lanzl I, Mackensen F, Ness T, Pleyer
U, Stuebiger N, Wilhelm B, Luedtke H, Zierhut M, Doycheva D; MYCUV-IIT02 Study
Group. Enteric-coated mycophenolate sodium in the treatment of non-infectious
intermediate uveitis: results of a prospective, controlled, randomised,
open-label, early terminated multicentre trial. Br J Ophthalmol. 2017 Sep 13.
pii: bjophthalmol-2017-310156. doi: 10.1136/bjophthalmol-2017-310156. [Epub ahead
of print] PubMed PMID: 28903965.

2: Zhang J, Jia M, Zuo L, Li N, Luo Y, Sun Z, Zhang X, Zhu Z. Nonlinear
relationship between enteric-coated mycophenolate sodium dose and mycophenolic
acid exposure in Han kidney transplantation recipients. Acta Pharm Sin B. 2017
May;7(3):347-352. doi: 10.1016/j.apsb.2016.11.003. Epub 2016 Dec 10. PubMed PMID:
28540172; PubMed Central PMCID: PMC5430868.

3: Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó
A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M, Cortés-Hernández J.
Enteric-coated mycophenolate sodium versus azathioprine in patients with active
systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017
Sep;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882. Epub 2017 Apr 27.
PubMed PMID: 28450313.

4: Genvigir FDV, Nishikawa AM, Felipe CR, Tedesco-Silva H Jr, Oliveira N, Salazar
ABC, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC. Influence of ABCC2,
CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based
Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy. 2017
May;37(5):535-545. doi: 10.1002/phar.1928. Epub 2017 May 9. PubMed PMID:
28316087.

5: Fernández-Codina A, Francisco-Pascual J, Fonollosa-Plà V. Successful treatment
of constrictive chronic pericarditis with mycophenolate sodium in a patient with
systemic sclerosis. Med Clin (Barc). 2017 Jun 21;148(12):574-575. doi:
10.1016/j.medcli.2017.01.027. Epub 2017 Mar 7. English, Spanish. PubMed PMID:
28283274.

6: van Doesum WB, Gard L, Bemelman FJ, de Fijter JW, Homan van der Heide JJ,
Niesters HG, van Son WJ, Stegeman CA, Groen H, Riezebos-Brilman A, Sanders JSF.
Incidence and outcome of BK polyomavirus infection in a multicenter randomized
controlled trial with renal transplant patients receiving cyclosporine-,
mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy.
Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12687. Epub 2017 May 4.
PubMed PMID: 28258601.